nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—kidney cancer—muscle cancer	0.432	1	CtDrD
Sunitinib—KIT—muscle cancer	0.212	1	CbGaD
Sunitinib—ABCG2—Dactinomycin—muscle cancer	0.0133	0.114	CbGbCtD
Sunitinib—ABCC4—Methotrexate—muscle cancer	0.00922	0.0794	CbGbCtD
Sunitinib—ABCC2—Vincristine—muscle cancer	0.00906	0.078	CbGbCtD
Sunitinib—ABCC2—Etoposide—muscle cancer	0.0083	0.0715	CbGbCtD
Sunitinib—ABCG2—Vincristine—muscle cancer	0.00819	0.0705	CbGbCtD
Sunitinib—ABCG2—Etoposide—muscle cancer	0.0075	0.0646	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.00605	0.0521	CbGbCtD
Sunitinib—CYP3A7—Vincristine—muscle cancer	0.00605	0.0521	CbGbCtD
Sunitinib—ABCC2—Doxorubicin—muscle cancer	0.00566	0.0487	CbGbCtD
Sunitinib—ABCC2—Methotrexate—muscle cancer	0.00548	0.0472	CbGbCtD
Sunitinib—ABCG2—Doxorubicin—muscle cancer	0.00512	0.0441	CbGbCtD
Sunitinib—ABCG2—Methotrexate—muscle cancer	0.00496	0.0427	CbGbCtD
Sunitinib—ABCB1—Dactinomycin—muscle cancer	0.00479	0.0413	CbGbCtD
Sunitinib—CYP3A5—Vincristine—muscle cancer	0.00454	0.0391	CbGbCtD
Sunitinib—CYP3A5—Etoposide—muscle cancer	0.00416	0.0358	CbGbCtD
Sunitinib—ABCB1—Vincristine—muscle cancer	0.00295	0.0254	CbGbCtD
Sunitinib—ABCB1—Etoposide—muscle cancer	0.00271	0.0233	CbGbCtD
Sunitinib—ABCB1—Doxorubicin—muscle cancer	0.00185	0.0159	CbGbCtD
Sunitinib—ABCB1—Methotrexate—muscle cancer	0.00179	0.0154	CbGbCtD
Sunitinib—CYP3A4—Vincristine—muscle cancer	0.00177	0.0152	CbGbCtD
Sunitinib—CYP3A4—Etoposide—muscle cancer	0.00162	0.014	CbGbCtD
Sunitinib—CYP3A4—Doxorubicin—muscle cancer	0.00111	0.00952	CbGbCtD
Sunitinib—STK24—Teniposide—Etoposide—muscle cancer	0.000523	0.232	CbGdCrCtD
Sunitinib—CHEK2—Vindesine—Vincristine—muscle cancer	0.000233	0.103	CbGdCrCtD
Sunitinib—PLK4—Teniposide—Etoposide—muscle cancer	0.000166	0.074	CbGdCrCtD
Sunitinib—CHEK2—Vinorelbine—Vincristine—muscle cancer	0.000147	0.0652	CbGdCrCtD
Sunitinib—CHEK2—Teniposide—Etoposide—muscle cancer	0.000147	0.0652	CbGdCrCtD
Sunitinib—CHEK2—Podofilox—Etoposide—muscle cancer	0.000147	0.0652	CbGdCrCtD
Sunitinib—DYRK1A—Epirubicin—Doxorubicin—muscle cancer	0.000118	0.0522	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Doxorubicin—muscle cancer	0.000118	0.0522	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Doxorubicin—muscle cancer	0.000118	0.0522	CbGdCrCtD
Sunitinib—BMP2K—tendon—muscle cancer	0.000114	0.00136	CbGeAlD
Sunitinib—STK3—head—muscle cancer	0.000114	0.00136	CbGeAlD
Sunitinib—MAP4K4—vagina—muscle cancer	0.000113	0.00136	CbGeAlD
Sunitinib—FLT1—smooth muscle tissue—muscle cancer	0.000113	0.00136	CbGeAlD
Sunitinib—CSNK1A1—bone marrow—muscle cancer	0.000113	0.00135	CbGeAlD
Sunitinib—DAPK3—testis—muscle cancer	0.000113	0.00135	CbGeAlD
Sunitinib—LRRK2—tendon—muscle cancer	0.000113	0.00135	CbGeAlD
Sunitinib—NUAK2—vagina—muscle cancer	0.000113	0.00135	CbGeAlD
Sunitinib—CLK1—bone marrow—muscle cancer	0.000112	0.00134	CbGeAlD
Sunitinib—ROCK1—head—muscle cancer	0.000112	0.00134	CbGeAlD
Sunitinib—MAP3K12—vagina—muscle cancer	0.000112	0.00134	CbGeAlD
Sunitinib—CLK2—testis—muscle cancer	0.000112	0.00134	CbGeAlD
Sunitinib—RPS6KB1—cardiac atrium—muscle cancer	0.000112	0.00134	CbGeAlD
Sunitinib—MAP4K2—testis—muscle cancer	0.000111	0.00133	CbGeAlD
Sunitinib—AXL—cardiac atrium—muscle cancer	0.00011	0.00132	CbGeAlD
Sunitinib—RPS6KA3—vagina—muscle cancer	0.00011	0.00132	CbGeAlD
Sunitinib—BMP2K—bone marrow—muscle cancer	0.00011	0.00132	CbGeAlD
Sunitinib—CAMK2G—bone marrow—muscle cancer	0.00011	0.00132	CbGeAlD
Sunitinib—PTK2B—tendon—muscle cancer	0.00011	0.00131	CbGeAlD
Sunitinib—STK3—testis—muscle cancer	0.00011	0.00131	CbGeAlD
Sunitinib—DYRK1A—head—muscle cancer	0.000109	0.00131	CbGeAlD
Sunitinib—LRRK2—bone marrow—muscle cancer	0.000109	0.00131	CbGeAlD
Sunitinib—FLT1—renal system—muscle cancer	0.000109	0.00131	CbGeAlD
Sunitinib—ROCK1—testis—muscle cancer	0.000108	0.0013	CbGeAlD
Sunitinib—YES1—smooth muscle tissue—muscle cancer	0.000108	0.0013	CbGeAlD
Sunitinib—CSNK1A1—vagina—muscle cancer	0.000108	0.0013	CbGeAlD
Sunitinib—CSNK1E—tendon—muscle cancer	0.000108	0.00129	CbGeAlD
Sunitinib—FGFR1—tendon—muscle cancer	0.000108	0.00129	CbGeAlD
Sunitinib—KIT—embryo—muscle cancer	0.000108	0.00129	CbGeAlD
Sunitinib—PRKAA1—bone marrow—muscle cancer	0.000108	0.00129	CbGeAlD
Sunitinib—CLK1—vagina—muscle cancer	0.000107	0.00129	CbGeAlD
Sunitinib—MERTK—head—muscle cancer	0.000107	0.00128	CbGeAlD
Sunitinib—PTK2B—bone marrow—muscle cancer	0.000106	0.00127	CbGeAlD
Sunitinib—IRAK4—tendon—muscle cancer	0.000106	0.00127	CbGeAlD
Sunitinib—SLK—cardiac atrium—muscle cancer	0.000106	0.00127	CbGeAlD
Sunitinib—PDGFRA—smooth muscle tissue—muscle cancer	0.000106	0.00127	CbGeAlD
Sunitinib—FLT4—bone marrow—muscle cancer	0.000106	0.00127	CbGeAlD
Sunitinib—DYRK1A—testis—muscle cancer	0.000106	0.00126	CbGeAlD
Sunitinib—CAMK2G—vagina—muscle cancer	0.000106	0.00126	CbGeAlD
Sunitinib—BMP2K—vagina—muscle cancer	0.000106	0.00126	CbGeAlD
Sunitinib—PDGFRB—embryo—muscle cancer	0.000105	0.00126	CbGeAlD
Sunitinib—JAK2—cardiac atrium—muscle cancer	0.000105	0.00126	CbGeAlD
Sunitinib—MAP4K4—head—muscle cancer	0.000105	0.00126	CbGeAlD
Sunitinib—LRRK2—vagina—muscle cancer	0.000105	0.00125	CbGeAlD
Sunitinib—YES1—renal system—muscle cancer	0.000104	0.00125	CbGeAlD
Sunitinib—ULK3—tendon—muscle cancer	0.000104	0.00125	CbGeAlD
Sunitinib—MAP2K2—tendon—muscle cancer	0.000104	0.00125	CbGeAlD
Sunitinib—FYN—cardiac atrium—muscle cancer	0.000103	0.00124	CbGeAlD
Sunitinib—MAP3K12—head—muscle cancer	0.000103	0.00124	CbGeAlD
Sunitinib—STK10—renal system—muscle cancer	0.000103	0.00124	CbGeAlD
Sunitinib—MERTK—testis—muscle cancer	0.000103	0.00124	CbGeAlD
Sunitinib—IRAK4—bone marrow—muscle cancer	0.000103	0.00123	CbGeAlD
Sunitinib—TAOK3—renal system—muscle cancer	0.000103	0.00123	CbGeAlD
Sunitinib—MAP3K7—tendon—muscle cancer	0.000102	0.00122	CbGeAlD
Sunitinib—PDGFRA—renal system—muscle cancer	0.000102	0.00122	CbGeAlD
Sunitinib—RPS6KA3—head—muscle cancer	0.000102	0.00122	CbGeAlD
Sunitinib—PTK2B—vagina—muscle cancer	0.000102	0.00122	CbGeAlD
Sunitinib—PRPF4—Daunorubicin—Doxorubicin—muscle cancer	0.000101	0.0451	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Doxorubicin—muscle cancer	0.000101	0.0451	CbGdCrCtD
Sunitinib—MAP4K4—testis—muscle cancer	0.000101	0.00121	CbGeAlD
Sunitinib—MAP2K1—head—muscle cancer	0.000101	0.00121	CbGeAlD
Sunitinib—TBK1—tendon—muscle cancer	0.000101	0.00121	CbGeAlD
Sunitinib—MAP3K3—cardiac atrium—muscle cancer	0.000101	0.00121	CbGeAlD
Sunitinib—MAP4K5—cardiac atrium—muscle cancer	0.000101	0.00121	CbGeAlD
Sunitinib—CHEK2—Vinblastine—Vincristine—muscle cancer	0.000101	0.0449	CbGdCrCtD
Sunitinib—MAP2K2—bone marrow—muscle cancer	0.000101	0.00121	CbGeAlD
Sunitinib—ULK3—bone marrow—muscle cancer	0.000101	0.00121	CbGeAlD
Sunitinib—NUAK2—testis—muscle cancer	0.000101	0.0012	CbGeAlD
Sunitinib—TYK2—tendon—muscle cancer	0.0001	0.0012	CbGeAlD
Sunitinib—CSNK1E—vagina—muscle cancer	0.0001	0.0012	CbGeAlD
Sunitinib—FGFR1—vagina—muscle cancer	0.0001	0.0012	CbGeAlD
Sunitinib—MAP3K2—bone marrow—muscle cancer	0.0001	0.0012	CbGeAlD
Sunitinib—CSNK1A1—head—muscle cancer	9.99e-05	0.0012	CbGeAlD
Sunitinib—MAP3K12—testis—muscle cancer	9.98e-05	0.0012	CbGeAlD
Sunitinib—FLT3—testis—muscle cancer	9.98e-05	0.0012	CbGeAlD
Sunitinib—CLK1—head—muscle cancer	9.93e-05	0.00119	CbGeAlD
Sunitinib—IRAK1—tendon—muscle cancer	9.91e-05	0.00119	CbGeAlD
Sunitinib—MAP3K7—bone marrow—muscle cancer	9.91e-05	0.00119	CbGeAlD
Sunitinib—IRAK4—vagina—muscle cancer	9.87e-05	0.00118	CbGeAlD
Sunitinib—RPS6KA3—testis—muscle cancer	9.85e-05	0.00118	CbGeAlD
Sunitinib—TBK1—bone marrow—muscle cancer	9.79e-05	0.00117	CbGeAlD
Sunitinib—MAP2K1—testis—muscle cancer	9.78e-05	0.00117	CbGeAlD
Sunitinib—FLT1—cardiac atrium—muscle cancer	9.77e-05	0.00117	CbGeAlD
Sunitinib—CAMK2G—head—muscle cancer	9.75e-05	0.00117	CbGeAlD
Sunitinib—BMP2K—head—muscle cancer	9.75e-05	0.00117	CbGeAlD
Sunitinib—TYK2—bone marrow—muscle cancer	9.73e-05	0.00116	CbGeAlD
Sunitinib—RPS6KB1—tendon—muscle cancer	9.73e-05	0.00116	CbGeAlD
Sunitinib—RET—tendon—muscle cancer	9.67e-05	0.00116	CbGeAlD
Sunitinib—FGR—tendon—muscle cancer	9.67e-05	0.00116	CbGeAlD
Sunitinib—LRRK2—head—muscle cancer	9.66e-05	0.00116	CbGeAlD
Sunitinib—EPHB6—cardiac atrium—muscle cancer	9.66e-05	0.00116	CbGeAlD
Sunitinib—CSNK1A1—testis—muscle cancer	9.65e-05	0.00116	CbGeAlD
Sunitinib—ULK3—vagina—muscle cancer	9.65e-05	0.00116	CbGeAlD
Sunitinib—AXL—tendon—muscle cancer	9.63e-05	0.00115	CbGeAlD
Sunitinib—IRAK1—bone marrow—muscle cancer	9.6e-05	0.00115	CbGeAlD
Sunitinib—CLK1—testis—muscle cancer	9.59e-05	0.00115	CbGeAlD
Sunitinib—KDR—smooth muscle tissue—muscle cancer	9.58e-05	0.00115	CbGeAlD
Sunitinib—PRKAA1—head—muscle cancer	9.52e-05	0.00114	CbGeAlD
Sunitinib—MAP3K7—vagina—muscle cancer	9.49e-05	0.00114	CbGeAlD
Sunitinib—RPS6KB1—bone marrow—muscle cancer	9.42e-05	0.00113	CbGeAlD
Sunitinib—CAMK2G—testis—muscle cancer	9.41e-05	0.00113	CbGeAlD
Sunitinib—BMP2K—testis—muscle cancer	9.41e-05	0.00113	CbGeAlD
Sunitinib—PTK2B—head—muscle cancer	9.41e-05	0.00113	CbGeAlD
Sunitinib—FLT4—head—muscle cancer	9.39e-05	0.00112	CbGeAlD
Sunitinib—TBK1—vagina—muscle cancer	9.38e-05	0.00112	CbGeAlD
Sunitinib—FGR—bone marrow—muscle cancer	9.36e-05	0.00112	CbGeAlD
Sunitinib—CSF1R—smooth muscle tissue—muscle cancer	9.35e-05	0.00112	CbGeAlD
Sunitinib—YES1—cardiac atrium—muscle cancer	9.33e-05	0.00112	CbGeAlD
Sunitinib—LRRK2—testis—muscle cancer	9.33e-05	0.00112	CbGeAlD
Sunitinib—TYK2—vagina—muscle cancer	9.32e-05	0.00112	CbGeAlD
Sunitinib—SLK—tendon—muscle cancer	9.27e-05	0.00111	CbGeAlD
Sunitinib—CSNK1E—head—muscle cancer	9.26e-05	0.00111	CbGeAlD
Sunitinib—KDR—renal system—muscle cancer	9.22e-05	0.0011	CbGeAlD
Sunitinib—TAOK3—cardiac atrium—muscle cancer	9.21e-05	0.0011	CbGeAlD
Sunitinib—PRKAA1—testis—muscle cancer	9.2e-05	0.0011	CbGeAlD
Sunitinib—JAK2—tendon—muscle cancer	9.14e-05	0.00109	CbGeAlD
Sunitinib—IRAK4—head—muscle cancer	9.12e-05	0.00109	CbGeAlD
Sunitinib—PTK2B—testis—muscle cancer	9.09e-05	0.00109	CbGeAlD
Sunitinib—FLT4—testis—muscle cancer	9.07e-05	0.00109	CbGeAlD
Sunitinib—RPS6KB1—vagina—muscle cancer	9.03e-05	0.00108	CbGeAlD
Sunitinib—FYN—tendon—muscle cancer	9.01e-05	0.00108	CbGeAlD
Sunitinib—SLK—bone marrow—muscle cancer	8.98e-05	0.00108	CbGeAlD
Sunitinib—FGR—vagina—muscle cancer	8.97e-05	0.00107	CbGeAlD
Sunitinib—CSNK1E—testis—muscle cancer	8.95e-05	0.00107	CbGeAlD
Sunitinib—FGFR1—testis—muscle cancer	8.95e-05	0.00107	CbGeAlD
Sunitinib—AXL—vagina—muscle cancer	8.93e-05	0.00107	CbGeAlD
Sunitinib—MAP2K2—head—muscle cancer	8.91e-05	0.00107	CbGeAlD
Sunitinib—ULK3—head—muscle cancer	8.91e-05	0.00107	CbGeAlD
Sunitinib—JAK2—bone marrow—muscle cancer	8.85e-05	0.00106	CbGeAlD
Sunitinib—MAP3K2—head—muscle cancer	8.85e-05	0.00106	CbGeAlD
Sunitinib—MAP4K5—tendon—muscle cancer	8.81e-05	0.00105	CbGeAlD
Sunitinib—MAP3K3—tendon—muscle cancer	8.81e-05	0.00105	CbGeAlD
Sunitinib—IRAK4—testis—muscle cancer	8.81e-05	0.00105	CbGeAlD
Sunitinib—FYN—bone marrow—muscle cancer	8.73e-05	0.00105	CbGeAlD
Sunitinib—TBK1—head—muscle cancer	8.67e-05	0.00104	CbGeAlD
Sunitinib—MAP2K2—testis—muscle cancer	8.61e-05	0.00103	CbGeAlD
Sunitinib—ULK3—testis—muscle cancer	8.61e-05	0.00103	CbGeAlD
Sunitinib—TYK2—head—muscle cancer	8.61e-05	0.00103	CbGeAlD
Sunitinib—SLK—vagina—muscle cancer	8.6e-05	0.00103	CbGeAlD
Sunitinib—MAP3K2—testis—muscle cancer	8.55e-05	0.00102	CbGeAlD
Sunitinib—MAP4K5—bone marrow—muscle cancer	8.53e-05	0.00102	CbGeAlD
Sunitinib—MAP3K3—bone marrow—muscle cancer	8.53e-05	0.00102	CbGeAlD
Sunitinib—FLT1—tendon—muscle cancer	8.51e-05	0.00102	CbGeAlD
Sunitinib—KIT—smooth muscle tissue—muscle cancer	8.49e-05	0.00102	CbGeAlD
Sunitinib—JAK2—vagina—muscle cancer	8.48e-05	0.00102	CbGeAlD
Sunitinib—MAP3K7—testis—muscle cancer	8.47e-05	0.00101	CbGeAlD
Sunitinib—EPHB6—tendon—muscle cancer	8.42e-05	0.00101	CbGeAlD
Sunitinib—TBK1—testis—muscle cancer	8.37e-05	0.001	CbGeAlD
Sunitinib—FYN—vagina—muscle cancer	8.36e-05	0.001	CbGeAlD
Sunitinib—RPS6KB1—head—muscle cancer	8.34e-05	0.000998	CbGeAlD
Sunitinib—TYK2—testis—muscle cancer	8.32e-05	0.000996	CbGeAlD
Sunitinib—PDGFRB—smooth muscle tissue—muscle cancer	8.29e-05	0.000993	CbGeAlD
Sunitinib—FGR—head—muscle cancer	8.29e-05	0.000992	CbGeAlD
Sunitinib—RET—head—muscle cancer	8.29e-05	0.000992	CbGeAlD
Sunitinib—KDR—cardiac atrium—muscle cancer	8.26e-05	0.000989	CbGeAlD
Sunitinib—MAP2K5—cardiac atrium—muscle cancer	8.26e-05	0.000989	CbGeAlD
Sunitinib—AXL—head—muscle cancer	8.25e-05	0.000988	CbGeAlD
Sunitinib—IRAK1—testis—muscle cancer	8.21e-05	0.000983	CbGeAlD
Sunitinib—MAP4K5—vagina—muscle cancer	8.17e-05	0.000979	CbGeAlD
Sunitinib—MAP3K3—vagina—muscle cancer	8.17e-05	0.000979	CbGeAlD
Sunitinib—KIT—renal system—muscle cancer	8.17e-05	0.000978	CbGeAlD
Sunitinib—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	8.15e-05	0.00122	CcSEcCtD
Sunitinib—Nervous system disorder—Vincristine—muscle cancer	8.14e-05	0.00122	CcSEcCtD
Sunitinib—YES1—tendon—muscle cancer	8.13e-05	0.000974	CbGeAlD
Sunitinib—Thrombocytopenia—Vincristine—muscle cancer	8.12e-05	0.00122	CcSEcCtD
Sunitinib—Hepatic function abnormal—Doxorubicin—muscle cancer	8.11e-05	0.00121	CcSEcCtD
Sunitinib—Decreased appetite—Dactinomycin—muscle cancer	8.07e-05	0.00121	CcSEcCtD
Sunitinib—Dysgeusia—Etoposide—muscle cancer	8.06e-05	0.00121	CcSEcCtD
Sunitinib—STK10—tendon—muscle cancer	8.06e-05	0.000965	CbGeAlD
Sunitinib—CSF1R—cardiac atrium—muscle cancer	8.06e-05	0.000965	CbGeAlD
Sunitinib—RPS6KB1—testis—muscle cancer	8.05e-05	0.000964	CbGeAlD
Sunitinib—PLK4—Idarubicin—Doxorubicin—muscle cancer	8.03e-05	0.0357	CbGdCrCtD
Sunitinib—PLK4—Epirubicin—Doxorubicin—muscle cancer	8.03e-05	0.0357	CbGdCrCtD
Sunitinib—TAOK3—tendon—muscle cancer	8.03e-05	0.000961	CbGeAlD
Sunitinib—RET—testis—muscle cancer	8e-05	0.000959	CbGeAlD
Sunitinib—FGR—testis—muscle cancer	8e-05	0.000959	CbGeAlD
Sunitinib—Fatigue—Dactinomycin—muscle cancer	8e-05	0.0012	CcSEcCtD
Sunitinib—PDGFRB—renal system—muscle cancer	7.98e-05	0.000956	CbGeAlD
Sunitinib—PDGFRA—tendon—muscle cancer	7.98e-05	0.000955	CbGeAlD
Sunitinib—AXL—testis—muscle cancer	7.97e-05	0.000955	CbGeAlD
Sunitinib—Back pain—Etoposide—muscle cancer	7.96e-05	0.00119	CcSEcCtD
Sunitinib—Pain—Dactinomycin—muscle cancer	7.94e-05	0.00119	CcSEcCtD
Sunitinib—Muscle spasms—Etoposide—muscle cancer	7.92e-05	0.00119	CcSEcCtD
Sunitinib—Anorexia—Vincristine—muscle cancer	7.91e-05	0.00118	CcSEcCtD
Sunitinib—FLT1—vagina—muscle cancer	7.9e-05	0.000946	CbGeAlD
Sunitinib—Hepatic failure—Doxorubicin—muscle cancer	7.89e-05	0.00118	CcSEcCtD
Sunitinib—Eczema—Doxorubicin—muscle cancer	7.89e-05	0.00118	CcSEcCtD
Sunitinib—YES1—bone marrow—muscle cancer	7.88e-05	0.000943	CbGeAlD
Sunitinib—FGFR2—head—muscle cancer	7.87e-05	0.000943	CbGeAlD
Sunitinib—JAK2—head—muscle cancer	7.83e-05	0.000938	CbGeAlD
Sunitinib—Cardiac failure congestive—Doxorubicin—muscle cancer	7.82e-05	0.00117	CcSEcCtD
Sunitinib—EPHB6—vagina—muscle cancer	7.81e-05	0.000935	CbGeAlD
Sunitinib—STK10—bone marrow—muscle cancer	7.81e-05	0.000935	CbGeAlD
Sunitinib—TAOK3—bone marrow—muscle cancer	7.78e-05	0.000931	CbGeAlD
Sunitinib—FYN—head—muscle cancer	7.72e-05	0.000925	CbGeAlD
Sunitinib—Renal failure acute—Doxorubicin—muscle cancer	7.68e-05	0.00115	CcSEcCtD
Sunitinib—SLK—testis—muscle cancer	7.67e-05	0.000919	CbGeAlD
Sunitinib—Anaemia—Etoposide—muscle cancer	7.61e-05	0.00114	CcSEcCtD
Sunitinib—FGFR2—testis—muscle cancer	7.61e-05	0.000911	CbGeAlD
Sunitinib—Gastrointestinal pain—Dactinomycin—muscle cancer	7.59e-05	0.00114	CcSEcCtD
Sunitinib—Hot flush—Doxorubicin—muscle cancer	7.58e-05	0.00113	CcSEcCtD
Sunitinib—JAK2—testis—muscle cancer	7.57e-05	0.000906	CbGeAlD
Sunitinib—Liver function test abnormal—Methotrexate—muscle cancer	7.56e-05	0.00113	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Vincristine—muscle cancer	7.56e-05	0.00113	CcSEcCtD
Sunitinib—MAP3K3—head—muscle cancer	7.55e-05	0.000904	CbGeAlD
Sunitinib—MAP4K5—head—muscle cancer	7.55e-05	0.000904	CbGeAlD
Sunitinib—YES1—vagina—muscle cancer	7.55e-05	0.000904	CbGeAlD
Sunitinib—Menopausal symptoms—Doxorubicin—muscle cancer	7.52e-05	0.00113	CcSEcCtD
Sunitinib—Insomnia—Vincristine—muscle cancer	7.5e-05	0.00112	CcSEcCtD
Sunitinib—STK10—vagina—muscle cancer	7.48e-05	0.000896	CbGeAlD
Sunitinib—FYN—testis—muscle cancer	7.46e-05	0.000894	CbGeAlD
Sunitinib—Renal impairment—Doxorubicin—muscle cancer	7.45e-05	0.00112	CcSEcCtD
Sunitinib—TAOK3—vagina—muscle cancer	7.45e-05	0.000892	CbGeAlD
Sunitinib—Paraesthesia—Vincristine—muscle cancer	7.45e-05	0.00112	CcSEcCtD
Sunitinib—Dermatitis bullous—Doxorubicin—muscle cancer	7.42e-05	0.00111	CcSEcCtD
Sunitinib—PDGFRA—vagina—muscle cancer	7.4e-05	0.000886	CbGeAlD
Sunitinib—Toxic epidermal necrolysis—Methotrexate—muscle cancer	7.37e-05	0.0011	CcSEcCtD
Sunitinib—Leukopenia—Etoposide—muscle cancer	7.37e-05	0.0011	CcSEcCtD
Sunitinib—Abdominal pain—Dactinomycin—muscle cancer	7.34e-05	0.0011	CcSEcCtD
Sunitinib—Body temperature increased—Dactinomycin—muscle cancer	7.34e-05	0.0011	CcSEcCtD
Sunitinib—FLT1—head—muscle cancer	7.3e-05	0.000874	CbGeAlD
Sunitinib—MAP3K3—testis—muscle cancer	7.29e-05	0.000873	CbGeAlD
Sunitinib—MAP4K5—testis—muscle cancer	7.29e-05	0.000873	CbGeAlD
Sunitinib—Hypoglycaemia—Doxorubicin—muscle cancer	7.27e-05	0.00109	CcSEcCtD
Sunitinib—Cardiac failure—Doxorubicin—muscle cancer	7.27e-05	0.00109	CcSEcCtD
Sunitinib—Cerebrovascular accident—Doxorubicin—muscle cancer	7.24e-05	0.00108	CcSEcCtD
Sunitinib—EPHB6—head—muscle cancer	7.21e-05	0.000864	CbGeAlD
Sunitinib—Decreased appetite—Vincristine—muscle cancer	7.21e-05	0.00108	CcSEcCtD
Sunitinib—MAP2K5—tendon—muscle cancer	7.2e-05	0.000862	CbGeAlD
Sunitinib—KDR—tendon—muscle cancer	7.2e-05	0.000862	CbGeAlD
Sunitinib—Cough—Etoposide—muscle cancer	7.18e-05	0.00108	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Vincristine—muscle cancer	7.16e-05	0.00107	CcSEcCtD
Sunitinib—Fatigue—Vincristine—muscle cancer	7.15e-05	0.00107	CcSEcCtD
Sunitinib—PDGFRB—cardiac atrium—muscle cancer	7.15e-05	0.000856	CbGeAlD
Sunitinib—Convulsion—Etoposide—muscle cancer	7.13e-05	0.00107	CcSEcCtD
Sunitinib—Hyponatraemia—Doxorubicin—muscle cancer	7.12e-05	0.00107	CcSEcCtD
Sunitinib—Hypertension—Etoposide—muscle cancer	7.11e-05	0.00106	CcSEcCtD
Sunitinib—Pain—Vincristine—muscle cancer	7.09e-05	0.00106	CcSEcCtD
Sunitinib—Constipation—Vincristine—muscle cancer	7.09e-05	0.00106	CcSEcCtD
Sunitinib—Pain in extremity—Doxorubicin—muscle cancer	7.09e-05	0.00106	CcSEcCtD
Sunitinib—CHEK2—Epirubicin—Doxorubicin—muscle cancer	7.08e-05	0.0315	CbGdCrCtD
Sunitinib—FLT1—testis—muscle cancer	7.05e-05	0.000844	CbGeAlD
Sunitinib—CSF1R—tendon—muscle cancer	7.02e-05	0.000841	CbGeAlD
Sunitinib—Chest pain—Etoposide—muscle cancer	7.01e-05	0.00105	CcSEcCtD
Sunitinib—KDR—bone marrow—muscle cancer	6.97e-05	0.000835	CbGeAlD
Sunitinib—YES1—head—muscle cancer	6.97e-05	0.000835	CbGeAlD
Sunitinib—EPHB6—testis—muscle cancer	6.97e-05	0.000834	CbGeAlD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	6.96e-05	0.00104	CcSEcCtD
Sunitinib—Pancreatitis—Methotrexate—muscle cancer	6.94e-05	0.00104	CcSEcCtD
Sunitinib—STK10—head—muscle cancer	6.91e-05	0.000827	CbGeAlD
Sunitinib—TAOK3—head—muscle cancer	6.88e-05	0.000824	CbGeAlD
Sunitinib—Face oedema—Doxorubicin—muscle cancer	6.85e-05	0.00102	CcSEcCtD
Sunitinib—Hypersensitivity—Dactinomycin—muscle cancer	6.84e-05	0.00102	CcSEcCtD
Sunitinib—PDGFRA—head—muscle cancer	6.84e-05	0.000819	CbGeAlD
Sunitinib—CSF1R—bone marrow—muscle cancer	6.8e-05	0.000815	CbGeAlD
Sunitinib—Abdominal discomfort—Methotrexate—muscle cancer	6.79e-05	0.00102	CcSEcCtD
Sunitinib—Gastrointestinal pain—Vincristine—muscle cancer	6.78e-05	0.00102	CcSEcCtD
Sunitinib—YES1—testis—muscle cancer	6.73e-05	0.000806	CbGeAlD
Sunitinib—Pancytopenia—Methotrexate—muscle cancer	6.72e-05	0.00101	CcSEcCtD
Sunitinib—KDR—vagina—muscle cancer	6.68e-05	0.0008	CbGeAlD
Sunitinib—MAP2K5—vagina—muscle cancer	6.68e-05	0.0008	CbGeAlD
Sunitinib—Infection—Etoposide—muscle cancer	6.68e-05	0.000999	CcSEcCtD
Sunitinib—STK10—testis—muscle cancer	6.67e-05	0.000799	CbGeAlD
Sunitinib—Asthenia—Dactinomycin—muscle cancer	6.66e-05	0.000997	CcSEcCtD
Sunitinib—TAOK3—testis—muscle cancer	6.65e-05	0.000796	CbGeAlD
Sunitinib—Blood creatinine increased—Doxorubicin—muscle cancer	6.64e-05	0.000995	CcSEcCtD
Sunitinib—Neutropenia—Methotrexate—muscle cancer	6.62e-05	0.000991	CcSEcCtD
Sunitinib—PDGFRA—testis—muscle cancer	6.61e-05	0.000791	CbGeAlD
Sunitinib—Dehydration—Doxorubicin—muscle cancer	6.59e-05	0.000987	CcSEcCtD
Sunitinib—Thrombocytopenia—Etoposide—muscle cancer	6.58e-05	0.000985	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Methotrexate—muscle cancer	6.58e-05	0.000985	CcSEcCtD
Sunitinib—Abdominal pain—Vincristine—muscle cancer	6.56e-05	0.000982	CcSEcCtD
Sunitinib—Body temperature increased—Vincristine—muscle cancer	6.56e-05	0.000982	CcSEcCtD
Sunitinib—Liver function test abnormal—Doxorubicin—muscle cancer	6.55e-05	0.00098	CcSEcCtD
Sunitinib—Skin disorder—Etoposide—muscle cancer	6.53e-05	0.000977	CcSEcCtD
Sunitinib—CSF1R—vagina—muscle cancer	6.52e-05	0.00078	CbGeAlD
Sunitinib—Dry skin—Doxorubicin—muscle cancer	6.5e-05	0.000973	CcSEcCtD
Sunitinib—Abdominal pain upper—Doxorubicin—muscle cancer	6.48e-05	0.00097	CcSEcCtD
Sunitinib—Hypokalaemia—Doxorubicin—muscle cancer	6.45e-05	0.000966	CcSEcCtD
Sunitinib—Anorexia—Etoposide—muscle cancer	6.41e-05	0.000959	CcSEcCtD
Sunitinib—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	6.39e-05	0.000956	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	6.39e-05	0.000956	CcSEcCtD
Sunitinib—ABCC4—renal system—muscle cancer	6.35e-05	0.000761	CbGeAlD
Sunitinib—Diarrhoea—Dactinomycin—muscle cancer	6.35e-05	0.000951	CcSEcCtD
Sunitinib—Pneumonia—Methotrexate—muscle cancer	6.35e-05	0.00095	CcSEcCtD
Sunitinib—Nasopharyngitis—Doxorubicin—muscle cancer	6.34e-05	0.000949	CcSEcCtD
Sunitinib—Infestation NOS—Methotrexate—muscle cancer	6.31e-05	0.000945	CcSEcCtD
Sunitinib—Infestation—Methotrexate—muscle cancer	6.31e-05	0.000945	CcSEcCtD
Sunitinib—Depression—Methotrexate—muscle cancer	6.29e-05	0.000942	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Methotrexate—muscle cancer	6.26e-05	0.000937	CcSEcCtD
Sunitinib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	6.25e-05	0.000936	CcSEcCtD
Sunitinib—Muscular weakness—Doxorubicin—muscle cancer	6.25e-05	0.000936	CcSEcCtD
Sunitinib—PDGFRB—tendon—muscle cancer	6.23e-05	0.000746	CbGeAlD
Sunitinib—Renal failure—Methotrexate—muscle cancer	6.2e-05	0.000929	CcSEcCtD
Sunitinib—KIT—bone marrow—muscle cancer	6.18e-05	0.00074	CbGeAlD
Sunitinib—Abdominal distension—Doxorubicin—muscle cancer	6.17e-05	0.000924	CcSEcCtD
Sunitinib—MAP2K5—head—muscle cancer	6.17e-05	0.000739	CbGeAlD
Sunitinib—KDR—head—muscle cancer	6.17e-05	0.000739	CbGeAlD
Sunitinib—Stomatitis—Methotrexate—muscle cancer	6.15e-05	0.000921	CcSEcCtD
Sunitinib—ABCC2—renal system—muscle cancer	6.15e-05	0.000737	CbGeAlD
Sunitinib—Dysphagia—Doxorubicin—muscle cancer	6.13e-05	0.000918	CcSEcCtD
Sunitinib—Hypersensitivity—Vincristine—muscle cancer	6.11e-05	0.000915	CcSEcCtD
Sunitinib—PDGFRB—bone marrow—muscle cancer	6.03e-05	0.000723	CbGeAlD
Sunitinib—Paraesthesia—Etoposide—muscle cancer	6.03e-05	0.000903	CcSEcCtD
Sunitinib—CSF1R—head—muscle cancer	6.02e-05	0.000721	CbGeAlD
Sunitinib—Pancreatitis—Doxorubicin—muscle cancer	6.01e-05	0.0009	CcSEcCtD
Sunitinib—Dyspnoea—Etoposide—muscle cancer	5.99e-05	0.000897	CcSEcCtD
Sunitinib—Hepatobiliary disease—Methotrexate—muscle cancer	5.97e-05	0.000894	CcSEcCtD
Sunitinib—MAP2K5—testis—muscle cancer	5.96e-05	0.000714	CbGeAlD
Sunitinib—KDR—testis—muscle cancer	5.96e-05	0.000714	CbGeAlD
Sunitinib—Epistaxis—Methotrexate—muscle cancer	5.95e-05	0.000891	CcSEcCtD
Sunitinib—Asthenia—Vincristine—muscle cancer	5.95e-05	0.000891	CcSEcCtD
Sunitinib—KIT—vagina—muscle cancer	5.92e-05	0.000709	CbGeAlD
Sunitinib—Vomiting—Dactinomycin—muscle cancer	5.9e-05	0.000884	CcSEcCtD
Sunitinib—Bronchitis—Doxorubicin—muscle cancer	5.89e-05	0.000882	CcSEcCtD
Sunitinib—Rash—Dactinomycin—muscle cancer	5.85e-05	0.000876	CcSEcCtD
Sunitinib—Decreased appetite—Etoposide—muscle cancer	5.84e-05	0.000875	CcSEcCtD
Sunitinib—Pancytopenia—Doxorubicin—muscle cancer	5.82e-05	0.000871	CcSEcCtD
Sunitinib—CSF1R—testis—muscle cancer	5.82e-05	0.000696	CbGeAlD
Sunitinib—Gastrointestinal disorder—Etoposide—muscle cancer	5.8e-05	0.000869	CcSEcCtD
Sunitinib—Fatigue—Etoposide—muscle cancer	5.79e-05	0.000867	CcSEcCtD
Sunitinib—PDGFRB—vagina—muscle cancer	5.78e-05	0.000692	CbGeAlD
Sunitinib—Constipation—Etoposide—muscle cancer	5.75e-05	0.00086	CcSEcCtD
Sunitinib—Pain—Etoposide—muscle cancer	5.75e-05	0.00086	CcSEcCtD
Sunitinib—Neutropenia—Doxorubicin—muscle cancer	5.73e-05	0.000858	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Doxorubicin—muscle cancer	5.7e-05	0.000853	CcSEcCtD
Sunitinib—Haemoglobin—Methotrexate—muscle cancer	5.69e-05	0.000853	CcSEcCtD
Sunitinib—Diarrhoea—Vincristine—muscle cancer	5.68e-05	0.00085	CcSEcCtD
Sunitinib—Haemorrhage—Methotrexate—muscle cancer	5.67e-05	0.000848	CcSEcCtD
Sunitinib—Hepatitis—Methotrexate—muscle cancer	5.67e-05	0.000848	CcSEcCtD
Sunitinib—Urinary tract disorder—Methotrexate—muscle cancer	5.59e-05	0.000838	CcSEcCtD
Sunitinib—Urethral disorder—Methotrexate—muscle cancer	5.55e-05	0.000831	CcSEcCtD
Sunitinib—Weight decreased—Doxorubicin—muscle cancer	5.54e-05	0.00083	CcSEcCtD
Sunitinib—Hyperglycaemia—Doxorubicin—muscle cancer	5.53e-05	0.000828	CcSEcCtD
Sunitinib—Nausea—Dactinomycin—muscle cancer	5.51e-05	0.000826	CcSEcCtD
Sunitinib—Pneumonia—Doxorubicin—muscle cancer	5.5e-05	0.000823	CcSEcCtD
Sunitinib—Gastrointestinal pain—Etoposide—muscle cancer	5.49e-05	0.000823	CcSEcCtD
Sunitinib—Dizziness—Vincristine—muscle cancer	5.49e-05	0.000821	CcSEcCtD
Sunitinib—KIT—head—muscle cancer	5.47e-05	0.000655	CbGeAlD
Sunitinib—Infestation—Doxorubicin—muscle cancer	5.46e-05	0.000818	CcSEcCtD
Sunitinib—Infestation NOS—Doxorubicin—muscle cancer	5.46e-05	0.000818	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	5.42e-05	0.000811	CcSEcCtD
Sunitinib—Renal failure—Doxorubicin—muscle cancer	5.37e-05	0.000804	CcSEcCtD
Sunitinib—Erythema multiforme—Methotrexate—muscle cancer	5.36e-05	0.000802	CcSEcCtD
Sunitinib—Neuropathy peripheral—Doxorubicin—muscle cancer	5.36e-05	0.000802	CcSEcCtD
Sunitinib—PDGFRB—head—muscle cancer	5.34e-05	0.000639	CbGeAlD
Sunitinib—Stomatitis—Doxorubicin—muscle cancer	5.33e-05	0.000797	CcSEcCtD
Sunitinib—Abdominal pain—Etoposide—muscle cancer	5.31e-05	0.000795	CcSEcCtD
Sunitinib—Body temperature increased—Etoposide—muscle cancer	5.31e-05	0.000795	CcSEcCtD
Sunitinib—Urinary tract infection—Doxorubicin—muscle cancer	5.31e-05	0.000795	CcSEcCtD
Sunitinib—Eye disorder—Methotrexate—muscle cancer	5.29e-05	0.000793	CcSEcCtD
Sunitinib—KIT—testis—muscle cancer	5.28e-05	0.000632	CbGeAlD
Sunitinib—Vomiting—Vincristine—muscle cancer	5.27e-05	0.00079	CcSEcCtD
Sunitinib—Cardiac disorder—Methotrexate—muscle cancer	5.26e-05	0.000787	CcSEcCtD
Sunitinib—Rash—Vincristine—muscle cancer	5.23e-05	0.000783	CcSEcCtD
Sunitinib—Dermatitis—Vincristine—muscle cancer	5.23e-05	0.000782	CcSEcCtD
Sunitinib—Headache—Vincristine—muscle cancer	5.2e-05	0.000778	CcSEcCtD
Sunitinib—Hepatobiliary disease—Doxorubicin—muscle cancer	5.17e-05	0.000774	CcSEcCtD
Sunitinib—PDGFRB—testis—muscle cancer	5.16e-05	0.000618	CbGeAlD
Sunitinib—Epistaxis—Doxorubicin—muscle cancer	5.15e-05	0.000772	CcSEcCtD
Sunitinib—Angiopathy—Methotrexate—muscle cancer	5.14e-05	0.00077	CcSEcCtD
Sunitinib—Immune system disorder—Methotrexate—muscle cancer	5.12e-05	0.000766	CcSEcCtD
Sunitinib—Mediastinal disorder—Methotrexate—muscle cancer	5.11e-05	0.000764	CcSEcCtD
Sunitinib—Chills—Methotrexate—muscle cancer	5.08e-05	0.000761	CcSEcCtD
Sunitinib—KCNH2—renal system—muscle cancer	5.04e-05	0.000604	CbGeAlD
Sunitinib—Alopecia—Methotrexate—muscle cancer	5.01e-05	0.00075	CcSEcCtD
Sunitinib—Bradycardia—Doxorubicin—muscle cancer	4.99e-05	0.000748	CcSEcCtD
Sunitinib—Mental disorder—Methotrexate—muscle cancer	4.96e-05	0.000743	CcSEcCtD
Sunitinib—ABCC4—tendon—muscle cancer	4.96e-05	0.000594	CbGeAlD
Sunitinib—Hypersensitivity—Etoposide—muscle cancer	4.95e-05	0.000741	CcSEcCtD
Sunitinib—Malnutrition—Methotrexate—muscle cancer	4.93e-05	0.000738	CcSEcCtD
Sunitinib—Erythema—Methotrexate—muscle cancer	4.93e-05	0.000738	CcSEcCtD
Sunitinib—Haemoglobin—Doxorubicin—muscle cancer	4.93e-05	0.000738	CcSEcCtD
Sunitinib—Nausea—Vincristine—muscle cancer	4.93e-05	0.000738	CcSEcCtD
Sunitinib—Haemorrhage—Doxorubicin—muscle cancer	4.91e-05	0.000734	CcSEcCtD
Sunitinib—Hepatitis—Doxorubicin—muscle cancer	4.91e-05	0.000734	CcSEcCtD
Sunitinib—Hypoaesthesia—Doxorubicin—muscle cancer	4.88e-05	0.000731	CcSEcCtD
Sunitinib—Urinary tract disorder—Doxorubicin—muscle cancer	4.84e-05	0.000725	CcSEcCtD
Sunitinib—Oedema peripheral—Doxorubicin—muscle cancer	4.83e-05	0.000724	CcSEcCtD
Sunitinib—Dysgeusia—Methotrexate—muscle cancer	4.83e-05	0.000723	CcSEcCtD
Sunitinib—Asthenia—Etoposide—muscle cancer	4.82e-05	0.000722	CcSEcCtD
Sunitinib—Connective tissue disorder—Doxorubicin—muscle cancer	4.82e-05	0.000722	CcSEcCtD
Sunitinib—Urethral disorder—Doxorubicin—muscle cancer	4.81e-05	0.00072	CcSEcCtD
Sunitinib—ABCC4—bone marrow—muscle cancer	4.8e-05	0.000575	CbGeAlD
Sunitinib—ABCC2—tendon—muscle cancer	4.8e-05	0.000575	CbGeAlD
Sunitinib—Back pain—Methotrexate—muscle cancer	4.77e-05	0.000714	CcSEcCtD
Sunitinib—Pruritus—Etoposide—muscle cancer	4.75e-05	0.000712	CcSEcCtD
Sunitinib—Erythema multiforme—Doxorubicin—muscle cancer	4.64e-05	0.000694	CcSEcCtD
Sunitinib—Diarrhoea—Etoposide—muscle cancer	4.6e-05	0.000688	CcSEcCtD
Sunitinib—Eye disorder—Doxorubicin—muscle cancer	4.58e-05	0.000686	CcSEcCtD
Sunitinib—Anaemia—Methotrexate—muscle cancer	4.56e-05	0.000682	CcSEcCtD
Sunitinib—Flushing—Doxorubicin—muscle cancer	4.55e-05	0.000682	CcSEcCtD
Sunitinib—Cardiac disorder—Doxorubicin—muscle cancer	4.55e-05	0.000682	CcSEcCtD
Sunitinib—KCNH2—cardiac atrium—muscle cancer	4.52e-05	0.000541	CbGeAlD
Sunitinib—Angiopathy—Doxorubicin—muscle cancer	4.45e-05	0.000666	CcSEcCtD
Sunitinib—Dizziness—Etoposide—muscle cancer	4.44e-05	0.000665	CcSEcCtD
Sunitinib—Immune system disorder—Doxorubicin—muscle cancer	4.43e-05	0.000663	CcSEcCtD
Sunitinib—Mediastinal disorder—Doxorubicin—muscle cancer	4.42e-05	0.000662	CcSEcCtD
Sunitinib—Leukopenia—Methotrexate—muscle cancer	4.41e-05	0.000661	CcSEcCtD
Sunitinib—Chills—Doxorubicin—muscle cancer	4.4e-05	0.000659	CcSEcCtD
Sunitinib—Arrhythmia—Doxorubicin—muscle cancer	4.38e-05	0.000656	CcSEcCtD
Sunitinib—Alopecia—Doxorubicin—muscle cancer	4.33e-05	0.000649	CcSEcCtD
Sunitinib—Cough—Methotrexate—muscle cancer	4.3e-05	0.000644	CcSEcCtD
Sunitinib—Mental disorder—Doxorubicin—muscle cancer	4.3e-05	0.000643	CcSEcCtD
Sunitinib—Convulsion—Methotrexate—muscle cancer	4.27e-05	0.00064	CcSEcCtD
Sunitinib—Vomiting—Etoposide—muscle cancer	4.27e-05	0.00064	CcSEcCtD
Sunitinib—Malnutrition—Doxorubicin—muscle cancer	4.27e-05	0.000639	CcSEcCtD
Sunitinib—Erythema—Doxorubicin—muscle cancer	4.27e-05	0.000639	CcSEcCtD
Sunitinib—ABCC4—head—muscle cancer	4.25e-05	0.000509	CbGeAlD
Sunitinib—Rash—Etoposide—muscle cancer	4.24e-05	0.000634	CcSEcCtD
Sunitinib—Dermatitis—Etoposide—muscle cancer	4.23e-05	0.000634	CcSEcCtD
Sunitinib—Headache—Etoposide—muscle cancer	4.21e-05	0.00063	CcSEcCtD
Sunitinib—Flatulence—Doxorubicin—muscle cancer	4.21e-05	0.00063	CcSEcCtD
Sunitinib—Chest pain—Methotrexate—muscle cancer	4.2e-05	0.000629	CcSEcCtD
Sunitinib—Arthralgia—Methotrexate—muscle cancer	4.2e-05	0.000629	CcSEcCtD
Sunitinib—Myalgia—Methotrexate—muscle cancer	4.2e-05	0.000629	CcSEcCtD
Sunitinib—Dysgeusia—Doxorubicin—muscle cancer	4.18e-05	0.000626	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	4.17e-05	0.000624	CcSEcCtD
Sunitinib—CYP3A5—renal system—muscle cancer	4.16e-05	0.000499	CbGeAlD
Sunitinib—Back pain—Doxorubicin—muscle cancer	4.13e-05	0.000618	CcSEcCtD
Sunitinib—ABCC4—testis—muscle cancer	4.11e-05	0.000492	CbGeAlD
Sunitinib—Muscle spasms—Doxorubicin—muscle cancer	4.11e-05	0.000615	CcSEcCtD
Sunitinib—Infection—Methotrexate—muscle cancer	4e-05	0.000599	CcSEcCtD
Sunitinib—Nausea—Etoposide—muscle cancer	3.99e-05	0.000598	CcSEcCtD
Sunitinib—ABCC2—testis—muscle cancer	3.98e-05	0.000476	CbGeAlD
Sunitinib—Nervous system disorder—Methotrexate—muscle cancer	3.95e-05	0.000591	CcSEcCtD
Sunitinib—Anaemia—Doxorubicin—muscle cancer	3.95e-05	0.000591	CcSEcCtD
Sunitinib—Thrombocytopenia—Methotrexate—muscle cancer	3.94e-05	0.00059	CcSEcCtD
Sunitinib—Skin disorder—Methotrexate—muscle cancer	3.91e-05	0.000585	CcSEcCtD
Sunitinib—Anorexia—Methotrexate—muscle cancer	3.84e-05	0.000574	CcSEcCtD
Sunitinib—Leukopenia—Doxorubicin—muscle cancer	3.82e-05	0.000572	CcSEcCtD
Sunitinib—KCNH2—bone marrow—muscle cancer	3.81e-05	0.000457	CbGeAlD
Sunitinib—Cough—Doxorubicin—muscle cancer	3.73e-05	0.000558	CcSEcCtD
Sunitinib—Convulsion—Doxorubicin—muscle cancer	3.7e-05	0.000554	CcSEcCtD
Sunitinib—Hypertension—Doxorubicin—muscle cancer	3.69e-05	0.000552	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Methotrexate—muscle cancer	3.67e-05	0.000549	CcSEcCtD
Sunitinib—KCNH2—vagina—muscle cancer	3.65e-05	0.000437	CbGeAlD
Sunitinib—Insomnia—Methotrexate—muscle cancer	3.64e-05	0.000545	CcSEcCtD
Sunitinib—Chest pain—Doxorubicin—muscle cancer	3.64e-05	0.000544	CcSEcCtD
Sunitinib—Myalgia—Doxorubicin—muscle cancer	3.64e-05	0.000544	CcSEcCtD
Sunitinib—Arthralgia—Doxorubicin—muscle cancer	3.64e-05	0.000544	CcSEcCtD
Sunitinib—Paraesthesia—Methotrexate—muscle cancer	3.61e-05	0.000541	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	3.61e-05	0.000541	CcSEcCtD
Sunitinib—Dyspnoea—Methotrexate—muscle cancer	3.59e-05	0.000537	CcSEcCtD
Sunitinib—Dry mouth—Doxorubicin—muscle cancer	3.56e-05	0.000532	CcSEcCtD
Sunitinib—Dyspepsia—Methotrexate—muscle cancer	3.54e-05	0.00053	CcSEcCtD
Sunitinib—Decreased appetite—Methotrexate—muscle cancer	3.5e-05	0.000524	CcSEcCtD
Sunitinib—Oedema—Doxorubicin—muscle cancer	3.49e-05	0.000522	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Methotrexate—muscle cancer	3.47e-05	0.00052	CcSEcCtD
Sunitinib—Fatigue—Methotrexate—muscle cancer	3.47e-05	0.00052	CcSEcCtD
Sunitinib—Infection—Doxorubicin—muscle cancer	3.46e-05	0.000518	CcSEcCtD
Sunitinib—Pain—Methotrexate—muscle cancer	3.44e-05	0.000515	CcSEcCtD
Sunitinib—Shock—Doxorubicin—muscle cancer	3.43e-05	0.000513	CcSEcCtD
Sunitinib—Nervous system disorder—Doxorubicin—muscle cancer	3.42e-05	0.000512	CcSEcCtD
Sunitinib—Thrombocytopenia—Doxorubicin—muscle cancer	3.41e-05	0.000511	CcSEcCtD
Sunitinib—ABCG2—bone marrow—muscle cancer	3.39e-05	0.000406	CbGeAlD
Sunitinib—Skin disorder—Doxorubicin—muscle cancer	3.39e-05	0.000507	CcSEcCtD
Sunitinib—KCNH2—head—muscle cancer	3.37e-05	0.000404	CbGeAlD
Sunitinib—Anorexia—Doxorubicin—muscle cancer	3.32e-05	0.000497	CcSEcCtD
Sunitinib—Gastrointestinal pain—Methotrexate—muscle cancer	3.29e-05	0.000493	CcSEcCtD
Sunitinib—KCNH2—testis—muscle cancer	3.26e-05	0.00039	CbGeAlD
Sunitinib—ABCG2—vagina—muscle cancer	3.25e-05	0.000389	CbGeAlD
Sunitinib—Body temperature increased—Methotrexate—muscle cancer	3.18e-05	0.000476	CcSEcCtD
Sunitinib—Abdominal pain—Methotrexate—muscle cancer	3.18e-05	0.000476	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	3.18e-05	0.000475	CcSEcCtD
Sunitinib—Insomnia—Doxorubicin—muscle cancer	3.15e-05	0.000472	CcSEcCtD
Sunitinib—Paraesthesia—Doxorubicin—muscle cancer	3.13e-05	0.000469	CcSEcCtD
Sunitinib—CYP3A4—renal system—muscle cancer	3.12e-05	0.000374	CbGeAlD
Sunitinib—Dyspnoea—Doxorubicin—muscle cancer	3.11e-05	0.000465	CcSEcCtD
Sunitinib—Dyspepsia—Doxorubicin—muscle cancer	3.07e-05	0.000459	CcSEcCtD
Sunitinib—Decreased appetite—Doxorubicin—muscle cancer	3.03e-05	0.000454	CcSEcCtD
Sunitinib—CYP3A5—vagina—muscle cancer	3.02e-05	0.000361	CbGeAlD
Sunitinib—Gastrointestinal disorder—Doxorubicin—muscle cancer	3.01e-05	0.00045	CcSEcCtD
Sunitinib—Fatigue—Doxorubicin—muscle cancer	3e-05	0.00045	CcSEcCtD
Sunitinib—Pain—Doxorubicin—muscle cancer	2.98e-05	0.000446	CcSEcCtD
Sunitinib—Constipation—Doxorubicin—muscle cancer	2.98e-05	0.000446	CcSEcCtD
Sunitinib—Hypersensitivity—Methotrexate—muscle cancer	2.97e-05	0.000444	CcSEcCtD
Sunitinib—ABCB1—embryo—muscle cancer	2.92e-05	0.00035	CbGeAlD
Sunitinib—ABCG2—testis—muscle cancer	2.9e-05	0.000347	CbGeAlD
Sunitinib—Asthenia—Methotrexate—muscle cancer	2.89e-05	0.000432	CcSEcCtD
Sunitinib—Gastrointestinal pain—Doxorubicin—muscle cancer	2.85e-05	0.000427	CcSEcCtD
Sunitinib—Pruritus—Methotrexate—muscle cancer	2.85e-05	0.000426	CcSEcCtD
Sunitinib—Abdominal pain—Doxorubicin—muscle cancer	2.76e-05	0.000413	CcSEcCtD
Sunitinib—Body temperature increased—Doxorubicin—muscle cancer	2.76e-05	0.000413	CcSEcCtD
Sunitinib—Diarrhoea—Methotrexate—muscle cancer	2.75e-05	0.000412	CcSEcCtD
Sunitinib—Dizziness—Methotrexate—muscle cancer	2.66e-05	0.000398	CcSEcCtD
Sunitinib—Hypersensitivity—Doxorubicin—muscle cancer	2.57e-05	0.000384	CcSEcCtD
Sunitinib—Vomiting—Methotrexate—muscle cancer	2.56e-05	0.000383	CcSEcCtD
Sunitinib—Rash—Methotrexate—muscle cancer	2.54e-05	0.00038	CcSEcCtD
Sunitinib—Dermatitis—Methotrexate—muscle cancer	2.54e-05	0.00038	CcSEcCtD
Sunitinib—Headache—Methotrexate—muscle cancer	2.52e-05	0.000378	CcSEcCtD
Sunitinib—Asthenia—Doxorubicin—muscle cancer	2.5e-05	0.000374	CcSEcCtD
Sunitinib—Pruritus—Doxorubicin—muscle cancer	2.47e-05	0.000369	CcSEcCtD
Sunitinib—Nausea—Methotrexate—muscle cancer	2.39e-05	0.000358	CcSEcCtD
Sunitinib—Diarrhoea—Doxorubicin—muscle cancer	2.38e-05	0.000357	CcSEcCtD
Sunitinib—Dizziness—Doxorubicin—muscle cancer	2.3e-05	0.000345	CcSEcCtD
Sunitinib—Vomiting—Doxorubicin—muscle cancer	2.22e-05	0.000332	CcSEcCtD
Sunitinib—ABCB1—renal system—muscle cancer	2.21e-05	0.000265	CbGeAlD
Sunitinib—Rash—Doxorubicin—muscle cancer	2.2e-05	0.000329	CcSEcCtD
Sunitinib—Dermatitis—Doxorubicin—muscle cancer	2.2e-05	0.000329	CcSEcCtD
Sunitinib—Headache—Doxorubicin—muscle cancer	2.18e-05	0.000327	CcSEcCtD
Sunitinib—Nausea—Doxorubicin—muscle cancer	2.07e-05	0.00031	CcSEcCtD
Sunitinib—ABCB1—bone marrow—muscle cancer	1.67e-05	0.0002	CbGeAlD
Sunitinib—ABCB1—vagina—muscle cancer	1.6e-05	0.000192	CbGeAlD
Sunitinib—ABCB1—head—muscle cancer	1.48e-05	0.000177	CbGeAlD
Sunitinib—ABCB1—testis—muscle cancer	1.43e-05	0.000171	CbGeAlD
Sunitinib—FGFR1—Developmental Biology—VEGFA—muscle cancer	4e-06	4.56e-05	CbGpPWpGaD
Sunitinib—STK11—Signaling Pathways—VEGFA—muscle cancer	3.98e-06	4.54e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PTCH1—muscle cancer	3.98e-06	4.54e-05	CbGpPWpGaD
Sunitinib—BLK—Immune System—MDM2—muscle cancer	3.98e-06	4.53e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—FOXO1—muscle cancer	3.97e-06	4.52e-05	CbGpPWpGaD
Sunitinib—FGR—Immune System—MDM2—muscle cancer	3.96e-06	4.51e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PTCH1—muscle cancer	3.96e-06	4.51e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—FOXO4—muscle cancer	3.95e-06	4.51e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—FOXO4—muscle cancer	3.94e-06	4.49e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—KIT—muscle cancer	3.93e-06	4.47e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—FOXO1—muscle cancer	3.91e-06	4.46e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—FOXO1—muscle cancer	3.89e-06	4.43e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CNR1—muscle cancer	3.88e-06	4.42e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CNR1—muscle cancer	3.87e-06	4.41e-05	CbGpPWpGaD
Sunitinib—FYN—Adaptive Immune System—MDM2—muscle cancer	3.87e-06	4.41e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—KIT—muscle cancer	3.85e-06	4.39e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—FOXO1—muscle cancer	3.84e-06	4.38e-05	CbGpPWpGaD
Sunitinib—INSR—Signaling Pathways—VEGFA—muscle cancer	3.83e-06	4.37e-05	CbGpPWpGaD
Sunitinib—JAK2—Innate Immune System—MDM2—muscle cancer	3.83e-06	4.37e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—MDM2—muscle cancer	3.83e-06	4.36e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PTCH1—muscle cancer	3.79e-06	4.31e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—FOXO1—muscle cancer	3.75e-06	4.27e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—IGF2—muscle cancer	3.74e-06	4.27e-05	CbGpPWpGaD
Sunitinib—ABCC4—Hemostasis—VEGFA—muscle cancer	3.74e-06	4.26e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—KIT—muscle cancer	3.74e-06	4.26e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—FOXO1—muscle cancer	3.72e-06	4.24e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—KIT—muscle cancer	3.69e-06	4.21e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Developmental Biology—VEGFA—muscle cancer	3.69e-06	4.2e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—KIT—muscle cancer	3.68e-06	4.2e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—KIT—muscle cancer	3.65e-06	4.16e-05	CbGpPWpGaD
Sunitinib—CSNK2A1—Signaling Pathways—VEGFA—muscle cancer	3.64e-06	4.15e-05	CbGpPWpGaD
Sunitinib—FLT4—Signaling Pathways—VEGFA—muscle cancer	3.64e-06	4.15e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—FOXO4—muscle cancer	3.64e-06	4.15e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—KIT—muscle cancer	3.63e-06	4.13e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—FOXO1—muscle cancer	3.61e-06	4.12e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—MDM2—muscle cancer	3.61e-06	4.11e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—FOXO1—muscle cancer	3.59e-06	4.09e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—MDM2—muscle cancer	3.58e-06	4.08e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CNR1—muscle cancer	3.57e-06	4.07e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—FOXO4—muscle cancer	3.55e-06	4.05e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—IGF2—muscle cancer	3.55e-06	4.05e-05	CbGpPWpGaD
Sunitinib—PAK3—Signaling Pathways—VEGFA—muscle cancer	3.53e-06	4.03e-05	CbGpPWpGaD
Sunitinib—YES1—Hemostasis—TP53—muscle cancer	3.5e-06	3.99e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CNR1—muscle cancer	3.49e-06	3.97e-05	CbGpPWpGaD
Sunitinib—CSNK1G2—Signaling Pathways—TP53—muscle cancer	3.47e-06	3.96e-05	CbGpPWpGaD
Sunitinib—GRK1—Signaling Pathways—TP53—muscle cancer	3.47e-06	3.96e-05	CbGpPWpGaD
Sunitinib—FYN—Developmental Biology—VEGFA—muscle cancer	3.47e-06	3.95e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—KIT—muscle cancer	3.45e-06	3.93e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IGF2—muscle cancer	3.45e-06	3.93e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Developmental Biology—VEGFA—muscle cancer	3.45e-06	3.93e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—FOXO1—muscle cancer	3.45e-06	3.93e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—KIT—muscle cancer	3.44e-06	3.92e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—FOXO1—muscle cancer	3.43e-06	3.91e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—KIT—muscle cancer	3.43e-06	3.91e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—FOXO4—muscle cancer	3.43e-06	3.9e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—KIT—muscle cancer	3.41e-06	3.88e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—FOXO4—muscle cancer	3.41e-06	3.88e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IGF2—muscle cancer	3.4e-06	3.88e-05	CbGpPWpGaD
Sunitinib—FYN—Hemostasis—VEGFA—muscle cancer	3.4e-06	3.87e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CNR1—muscle cancer	3.36e-06	3.83e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CNR1—muscle cancer	3.34e-06	3.81e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IGF2—muscle cancer	3.34e-06	3.81e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IGF2—muscle cancer	3.34e-06	3.81e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—KIT—muscle cancer	3.34e-06	3.81e-05	CbGpPWpGaD
Sunitinib—JAK2—Developmental Biology—VEGFA—muscle cancer	3.29e-06	3.75e-05	CbGpPWpGaD
Sunitinib—AXL—Signaling Pathways—TP53—muscle cancer	3.29e-06	3.75e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—FOXO1—muscle cancer	3.27e-06	3.72e-05	CbGpPWpGaD
Sunitinib—PRKAA2—Signaling Pathways—VEGFA—muscle cancer	3.26e-06	3.71e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—FOXO4—muscle cancer	3.26e-06	3.71e-05	CbGpPWpGaD
Sunitinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	3.23e-06	3.68e-05	CbGpPWpGaD
Sunitinib—JAK2—Hemostasis—VEGFA—muscle cancer	3.23e-06	3.68e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—KIT—muscle cancer	3.22e-06	3.67e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—KIT—muscle cancer	3.2e-06	3.65e-05	CbGpPWpGaD
Sunitinib—YES1—Immune System—MDM2—muscle cancer	3.2e-06	3.64e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CNR1—muscle cancer	3.2e-06	3.64e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—MED12—muscle cancer	3.19e-06	3.63e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—KIT—muscle cancer	3.18e-06	3.62e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IGF2—muscle cancer	3.17e-06	3.62e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—FOXO1—muscle cancer	3.17e-06	3.61e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—KIT—muscle cancer	3.17e-06	3.61e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—KIT—muscle cancer	3.17e-06	3.61e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IGF2—muscle cancer	3.17e-06	3.61e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—FOXO1—muscle cancer	3.13e-06	3.57e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—KIT—muscle cancer	3.1e-06	3.54e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—KIT—muscle cancer	3.1e-06	3.54e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—KIT—muscle cancer	3.09e-06	3.52e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—MDM2—muscle cancer	3.09e-06	3.52e-05	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—VEGFA—muscle cancer	3.08e-06	3.51e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—FOXO1—muscle cancer	3.08e-06	3.51e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—FOXO1—muscle cancer	3.08e-06	3.51e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—VEGFA—muscle cancer	3.05e-06	3.47e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—MDM2—muscle cancer	3.03e-06	3.46e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—KIT—muscle cancer	3.02e-06	3.45e-05	CbGpPWpGaD
Sunitinib—STK11—Signaling Pathways—TP53—muscle cancer	3.01e-06	3.43e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—KIT—muscle cancer	2.98e-06	3.4e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—KIT—muscle cancer	2.97e-06	3.38e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—MDM2—muscle cancer	2.95e-06	3.36e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—KIT—muscle cancer	2.93e-06	3.33e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IGF2—muscle cancer	2.92e-06	3.33e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—FOXO1—muscle cancer	2.92e-06	3.33e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—FOXO1—muscle cancer	2.91e-06	3.32e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—MDM2—muscle cancer	2.91e-06	3.31e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—VEGFA—muscle cancer	2.91e-06	3.31e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—ENO2—muscle cancer	2.9e-06	3.31e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—MDM2—muscle cancer	2.9e-06	3.3e-05	CbGpPWpGaD
Sunitinib—INSR—Signaling Pathways—TP53—muscle cancer	2.9e-06	3.3e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—MDM2—muscle cancer	2.87e-06	3.27e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—MDM2—muscle cancer	2.86e-06	3.25e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—MDM2—muscle cancer	2.86e-06	3.25e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—KIT—muscle cancer	2.86e-06	3.25e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IGF2—muscle cancer	2.85e-06	3.25e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—KIT—muscle cancer	2.83e-06	3.23e-05	CbGpPWpGaD
Sunitinib—ABCC4—Hemostasis—TP53—muscle cancer	2.83e-06	3.22e-05	CbGpPWpGaD
Sunitinib—CSNK2A1—Signaling Pathways—TP53—muscle cancer	2.75e-06	3.14e-05	CbGpPWpGaD
Sunitinib—FLT4—Signaling Pathways—TP53—muscle cancer	2.75e-06	3.14e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—KIT—muscle cancer	2.75e-06	3.14e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IGF2—muscle cancer	2.75e-06	3.13e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—VEGFA—muscle cancer	2.74e-06	3.12e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—KIT—muscle cancer	2.74e-06	3.12e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IGF2—muscle cancer	2.73e-06	3.11e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—MDM2—muscle cancer	2.72e-06	3.1e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—VEGFA—muscle cancer	2.72e-06	3.1e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—MDM2—muscle cancer	2.71e-06	3.09e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—MDM2—muscle cancer	2.7e-06	3.08e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—FOXO1—muscle cancer	2.69e-06	3.06e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—MDM2—muscle cancer	2.69e-06	3.06e-05	CbGpPWpGaD
Sunitinib—PAK3—Signaling Pathways—TP53—muscle cancer	2.67e-06	3.04e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—MDM2—muscle cancer	2.64e-06	3e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—MDM2—muscle cancer	2.63e-06	3e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—KIT—muscle cancer	2.63e-06	2.99e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—FOXO1—muscle cancer	2.62e-06	2.99e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—PTGS2—muscle cancer	2.62e-06	2.99e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—FH—muscle cancer	2.62e-06	2.99e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—KIT—muscle cancer	2.62e-06	2.98e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IGF2—muscle cancer	2.61e-06	2.98e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—PTGS2—muscle cancer	2.59e-06	2.95e-05	CbGpPWpGaD
Sunitinib—FYN—Hemostasis—TP53—muscle cancer	2.57e-06	2.93e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—PTGS2—muscle cancer	2.54e-06	2.9e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—MDM2—muscle cancer	2.54e-06	2.89e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—FOXO1—muscle cancer	2.53e-06	2.88e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—MDM2—muscle cancer	2.52e-06	2.87e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—FOXO1—muscle cancer	2.52e-06	2.87e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—MDM2—muscle cancer	2.5e-06	2.85e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—MDM2—muscle cancer	2.5e-06	2.84e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—MDM2—muscle cancer	2.5e-06	2.84e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KIT—muscle cancer	2.49e-06	2.84e-05	CbGpPWpGaD
Sunitinib—PRKAA2—Signaling Pathways—TP53—muscle cancer	2.46e-06	2.81e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—MDM2—muscle cancer	2.44e-06	2.78e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—MDM2—muscle cancer	2.44e-06	2.78e-05	CbGpPWpGaD
Sunitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	2.44e-06	2.78e-05	CbGpPWpGaD
Sunitinib—JAK2—Hemostasis—TP53—muscle cancer	2.44e-06	2.78e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—MDM2—muscle cancer	2.44e-06	2.78e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KIT—muscle cancer	2.42e-06	2.75e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—PTGS2—muscle cancer	2.41e-06	2.75e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—PTGS2—muscle cancer	2.41e-06	2.74e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—FOXO1—muscle cancer	2.4e-06	2.74e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—MED12—muscle cancer	2.4e-06	2.74e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KIT—muscle cancer	2.39e-06	2.72e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—MDM2—muscle cancer	2.38e-06	2.71e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—MDM2—muscle cancer	2.35e-06	2.68e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—VEGFA—muscle cancer	2.35e-06	2.67e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KIT—muscle cancer	2.34e-06	2.67e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—MDM2—muscle cancer	2.34e-06	2.66e-05	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—TP53—muscle cancer	2.33e-06	2.65e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—MDM2—muscle cancer	2.3e-06	2.63e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—TP53—muscle cancer	2.3e-06	2.63e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—MDM2—muscle cancer	2.25e-06	2.56e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—MDM2—muscle cancer	2.23e-06	2.54e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KIT—muscle cancer	2.23e-06	2.54e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—PTGS2—muscle cancer	2.22e-06	2.53e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KIT—muscle cancer	2.22e-06	2.53e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—VEGFA—muscle cancer	2.2e-06	2.51e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—TP53—muscle cancer	2.2e-06	2.5e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ENO2—muscle cancer	2.19e-06	2.5e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—VEGFA—muscle cancer	2.18e-06	2.49e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—PTGS2—muscle cancer	2.17e-06	2.47e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—MDM2—muscle cancer	2.17e-06	2.47e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—MDM2—muscle cancer	2.16e-06	2.46e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—PTGS2—muscle cancer	2.09e-06	2.38e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—PTGS2—muscle cancer	2.08e-06	2.37e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—TP53—muscle cancer	2.07e-06	2.36e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—MDM2—muscle cancer	2.07e-06	2.36e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—MDM2—muscle cancer	2.06e-06	2.35e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—TP53—muscle cancer	2.05e-06	2.34e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KIT—muscle cancer	2.05e-06	2.33e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—VEGFA—muscle cancer	2e-06	2.28e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KIT—muscle cancer	2e-06	2.28e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—PTGS2—muscle cancer	1.99e-06	2.26e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MDM2—muscle cancer	1.96e-06	2.23e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KIT—muscle cancer	1.93e-06	2.2e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—VEGFA—muscle cancer	1.93e-06	2.19e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KIT—muscle cancer	1.92e-06	2.18e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—VEGFA—muscle cancer	1.91e-06	2.18e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MDM2—muscle cancer	1.9e-06	2.17e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MDM2—muscle cancer	1.88e-06	2.14e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—VEGFA—muscle cancer	1.86e-06	2.11e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—VEGFA—muscle cancer	1.86e-06	2.11e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MDM2—muscle cancer	1.85e-06	2.1e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MDM2—muscle cancer	1.85e-06	2.1e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KIT—muscle cancer	1.83e-06	2.09e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—VEGFA—muscle cancer	1.81e-06	2.06e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—TP53—muscle cancer	1.77e-06	2.02e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MDM2—muscle cancer	1.75e-06	2e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MDM2—muscle cancer	1.75e-06	1.99e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—TP53—muscle cancer	1.66e-06	1.9e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—TP53—muscle cancer	1.65e-06	1.88e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MDM2—muscle cancer	1.61e-06	1.84e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MDM2—muscle cancer	1.57e-06	1.79e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—VEGFA—muscle cancer	1.57e-06	1.79e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MDM2—muscle cancer	1.52e-06	1.73e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—TP53—muscle cancer	1.51e-06	1.72e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MDM2—muscle cancer	1.51e-06	1.72e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—VEGFA—muscle cancer	1.49e-06	1.7e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—MED12—muscle cancer	1.48e-06	1.69e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TP53—muscle cancer	1.46e-06	1.66e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TP53—muscle cancer	1.45e-06	1.65e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—VEGFA—muscle cancer	1.45e-06	1.65e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MDM2—muscle cancer	1.44e-06	1.64e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—VEGFA—muscle cancer	1.43e-06	1.63e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTGS2—muscle cancer	1.41e-06	1.61e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—VEGFA—muscle cancer	1.4e-06	1.6e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—VEGFA—muscle cancer	1.4e-06	1.6e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TP53—muscle cancer	1.4e-06	1.6e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TP53—muscle cancer	1.4e-06	1.6e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTGS2—muscle cancer	1.4e-06	1.59e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TP53—muscle cancer	1.37e-06	1.56e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ENO2—muscle cancer	1.35e-06	1.54e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—VEGFA—muscle cancer	1.33e-06	1.52e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—VEGFA—muscle cancer	1.33e-06	1.51e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—VEGFA—muscle cancer	1.23e-06	1.4e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—VEGFA—muscle cancer	1.2e-06	1.36e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—muscle cancer	1.19e-06	1.35e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—VEGFA—muscle cancer	1.15e-06	1.31e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—VEGFA—muscle cancer	1.15e-06	1.31e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—muscle cancer	1.13e-06	1.28e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—VEGFA—muscle cancer	1.1e-06	1.25e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—muscle cancer	1.09e-06	1.24e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—muscle cancer	1.08e-06	1.23e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—muscle cancer	1.06e-06	1.21e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—muscle cancer	1.06e-06	1.21e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTGS2—muscle cancer	1.01e-06	1.15e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—muscle cancer	1.01e-06	1.15e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—muscle cancer	1e-06	1.14e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—muscle cancer	9.26e-07	1.06e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—muscle cancer	9.04e-07	1.03e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—muscle cancer	8.71e-07	9.92e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—muscle cancer	8.66e-07	9.87e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—muscle cancer	8.28e-07	9.43e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTGS2—muscle cancer	7.63e-07	8.7e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS2—muscle cancer	4.7e-07	5.36e-06	CbGpPWpGaD
